Bill Meury joined Incyte in 2025 and is Chief Executive Officer (CEO) and a member of the Company’s Board of Directors. With over three decades of industry experience, Mr. Meury is a proven enterprise leader with expertise in organizational strategy, pipeline and commercial execution and capital allocation.

Prior to joining Incyte, Mr. Meury was CEO of Anthos, where he successfully scaled the company for its next stage of growth. Before joining Anthos Therapeutics, Mr. Meury served as President and CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Prior to Karuna, he served as a Partner at Hildred Capital Management, a private equity firm focusing on healthcare products and services.

Earlier in his career, Mr. Meury spent more than two decades at Allergan, serving as Chief Commercial Officer, managing a global business with fifty products, $16 billion in revenue and approximately 8,000 employees across a range of therapeutic areas. He also served as Allergan’s President, Branded Pharma and Executive Vice President, Commercial, North American Brands, and as Executive Vice President Commercial Operations at Forest Laboratories prior to its acquisition by Allergan.

Mr. Meury has experience across a broad range of therapeutics areas and has been involved with over 20 U.S. FDA approvals and new product launches, as well as 25 different BD&L transactions.

He received his Bachelor of Arts degree in Economics from the University of Maryland and currently serves on the board of The Jed Foundation.

Pablo J. Cagnoni, M.D., joined Incyte in 2023 and is President and Global Head of Research and Development. In his role, Dr. Cagnoni oversees Incyte’s research and development efforts across its portfolio of programs in Hematology, Oncology and Inflammation and Autoimmunity, including Dermatology.

Prior to joining Incyte, Dr. Cagnoni served as the Chief Executive Officer of Laronde, a company dedicated to the development of a new type of translatable ribonucleic acid (RNA) called endless RNA (eRNA), and held leadership roles at Rubius Therapeutics, Tizona Therapeutics, Onyx Pharmaceuticals and Novartis Oncology. Throughout his career as a pharmaceutical executive and oncologist, Dr. Cagnoni has advanced the development of breakthrough treatments, playing a key role in the development, approval and commercialization of more than 20 life-changing medicines.

Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine. He completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York, and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

Soni Basi joined Incyte in 2025 as Executive Vice President and Chief Human Resources Officer (CHRO). As a member of the Executive Leadership Team, she is responsible for shaping Incyte’s global human resources strategy, including talent acquisition, organizational design, professional development, total rewards and engagement initiatives.

With more than 25 years of experience in global HR and business leadership, Soni is recognized for leading high-performing teams and guiding organizations through transformation. Before joining Incyte, she was CHRO at Edelman, where she shaped the company’s first global people strategy. She previously held senior talent leadership roles at AIG, Allergan Pharmaceuticals, The Estée Lauder Companies and Schering-Plough.

Soni earned her M.A. and Ph.D. in Social Psychology from Bowling Green State University.

Steven Stein, M.D. joined Incyte in 2015 and currently serves as the Company’s Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In his role, he oversees global clinical development and global medical affairs. Prior to joining Incyte, he worked at Novartis Pharmaceuticals Corporation, most recently as Senior Vice President, U.S. Clinical Development & Medical Affairs for Novartis Oncology. Prior to his tenure at Novartis, Dr. Stein worked at GSK (formerly GlaxoSmithKline) as Vice President, Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein was previously an Assistant Professor in the Department of Medicine at the University of Pennsylvania, where he had also completed a fellowship in Hematology and Oncology. Dr. Stein earned his medical degree from the University of Witwatersrand in Johannesburg, South Africa.

Richard Hoffman joined Incyte in December 2025 as Executive Vice President and General Counsel. In this role, he serves as a key member of the Executive Leadership Team and is responsible for leading the Company’s global legal and compliance functions.

Mr. Hoffman is an accomplished legal and business leader with more than 20 years of experience advising and supporting biopharmaceutical and life science companies. Prior to joining Incyte, he was a Partner in Goodwin’s Life Sciences group, where he counseled a diverse portfolio of emerging and established biopharma organizations, including Anthos Therapeutics, Compass Therapeutics, Deciphera Pharmaceuticals, PepGen and Syntimmune, on corporate governance, strategic transactions, intellectual property and litigation.

Earlier in his career, Mr. Hoffman held senior leadership positions in the biotechnology industry at Hybridon (now Idera Pharmaceuticals) and Avitech. He holds a B.A. from Harvard College, a J.D. from Columbia Law School and an M.B.A. from The Wharton School of the University of Pennsylvania.

Suketu (Suky) Upadhyay joined Incyte in 2026 and is Executive Vice President and Chief Financial Officer (CFO). As a key member of the Executive Leadership Team, he is responsible for leading the Company’s global finance organization. Mr. Upadhyay has extensive experience in the healthcare sector and a proven track record of strengthening global financial operations and leading transformations that drive significant value.

Prior to joining Incyte, Mr. Upadhyay served as Executive Vice President and Chief Financial Officer at Zimmer Biomet, a leading manufacturer of orthopedic solutions. Prior to that, he held senior finance leadership roles at several major pharmaceutical companies, including Senior Vice President of Global Financial Operations at Bristol Myers Squibb and Executive Vice President and Chief Financial Officer at Endo International. Mr. Upadhyay also served as Interim Chief Financial Officer and Chief Accounting Officer at Becton Dickinson, and earlier in his career held global finance and business development roles at AstraZeneca and Johnson & Johnson. He holds a Bachelor of Science in Finance from Albright College and a Master of Business Administration (MBA) from Duke University’s Fuqua School of Business.

Dave Gardner joined Incyte in 2025 as Executive Vice President and Chief Strategy Officer. In his role, Dave will serve as a key member of the Executive Leadership Team and be responsible for the Company’s strategy and business development.

With more than 20 years of experience in biopharmaceutical investing and advising, Dave most recently served as a Partner at Rock Springs Capital Management, leading strategy across Oncology, Neurology, Immunology and Rare Diseases. Prior to that, he spent a decade at BlackRock as Vice President and Equity Research Analyst where he was responsible for investments across the Health Care sector.

Dave holds an MBA from Columbia Business School and a bachelor’s degree from the University of Virginia’s McIntire School of Commerce.

Mohamed Issa joined Incyte in January 2025 and is Executive Vice President and Head of U.S. Commercial. He has over 20 years of global leadership experience in pharmaceuticals, consumer healthcare, and med-tech, with expertise spanning strategy, commercialization, and business development. Before Incyte, Mohamed spent 13 years at Johnson & Johnson, where he held senior roles leading U.S. Immunology, Neuroscience and Oncology businesses. Earlier in his career, he was co-founder and CEO of a consumer healthcare company and held various roles in sales, brand management and strategy in bio-pharmaceuticals. Mohamed holds a Doctor of Pharmacy degree from St. John’s University and a Master of Business Administration (MBA) in finance and economics from New York University’s Stern School of Business.

Lee Heeson joined Incyte in October of 2024 as Executive Vice President and Head of Incyte International. In his role, Mr. Heeson will lead commercial activities for Incyte outside of the United States, including Europe, Japan, Canada and rest of the world.

Prior to joining Incyte, Lee was Executive Vice President, Commercial International at Seagen; President of International at Vifor Pharma and President of Worldwide Markets at Celgene following other executive positions at the company. Earlier in his career, Lee held leadership positions at Galderma and Schering-Plough.

Lee holds a Bachelor of Arts, with honors, from Sheffield Hallam University.

Nicole Katz joined Incyte in 2026 as Group Vice President, Head of Global Corporate Affairs. As a member of the Executive Leadership Team, Nicole oversees the Corporate Affairs & Communications function, which includes Global Communications, Product Communications & Patient Advocacy, Public Affairs and Government Affairs.

Nicole is a seasoned global communications and corporate affairs leader with more than 25 years of experience across a broad range of therapeutic areas and is known for delivering results that drive the business. Prior to joining Incyte, she was Vice President, Corporate Affairs and Customer Engagement, at Allergan Aesthetics, an AbbVie company. There she oversaw global communications and public relations programs, for a $5B business. Before this role, she led Corporate Communications and Media Relations at Allergan and in communications roles at Actavis and Forest Pharmaceuticals. Previously, Nicole worked as Creative Director for a communications agency partnering with clients including Johnson & Johnson, Morgan Stanley, and the U.S. Government.

Nicole earned her Bachelor of Science from Syracuse University’s Newhouse School of Public Communications.

Michael Morrissey joined Incyte in 2016 as Corporate Senior Vice President and Head of Global Technical Operations. He has more than 30 years of global pharmaceutical industry experience through prior positions in research and development, quality assurance and manufacturing. Most recently, Mr. Morrissey served as Corporate Vice President, Head of International Technical Operations at Celgene International, where he built the company’s internal production and distribution capabilities and launched its drugs worldwide. Prior to Celgene, he worked for Roche for 15 years in various positions. Mr. Morrissey holds a diploma in Physics and Applied Mathematics from the University of London.